Irinotecan Hydrochloride Trihydrate

• CAT Number: I007360
• CAS Number: 136572-09-3
• Molecular Formula: C33H45ClN4O9
• Molecular Weight: 677.18
• Purity: ≥95%
• Solubility: Soluble in DMSO
• Storage: 0 - 4°C for short term , or -20°C for long term.
• IUPAC Name: [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;trihydrate;hydrochloride
• InChI: InChI=1S/C33H38N4O6.ClH.3H2O/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;;;;/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1H;3*1H2/t33-;;;;/m0..../s1
• InChIKey: KLEAIHJJLUAXIQ-JDRGBKBRSA-N
• SMILES: O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O) =C7C=C65)=O)=C(CC)C4=C3.[H]Cl.[H]O[H].[H]O[H].[H]O[H]

Irinotecan hydrochloride trihydrate (CAT: I007360) is an antineoplastic drug used in the treatment of various types of cancer, particularly colorectal cancer. It is a water-soluble prodrug that is converted in the body to its active metabolite, SN-38, by carboxylesterase enzymes. SN-38 inhibits topoisomerase I, an enzyme involved in DNA replication and repair, leading to DNA damage and cell death. Irinotecan hydrochloride trihydrate has demonstrated efficacy against solid tumors and is commonly used in combination chemotherapy regimens. It has shown benefits in both first-line and second-line treatments for colorectal cancer, as well as other malignancies such as small-cell lung cancer and pancreatic cancer.

Overview of Clinical Research

Irinotecan hydrochloride is a DNA topoisomerase I inhibitor. The phase I study for pancreatic cancer is ongoing in China.

Reference

1: Goto A. [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule]. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:125-30. Review. Japanese. PubMed PMID: 16897987.
2: Terauchi F. [Irinotecan hydrochloride (CPT-11) for advanced cervical cancer]. Nihon Rinsho. 2004 Oct;62 Suppl 10:175-8. Review. Japanese. PubMed PMID: 15535228.
3: Saijo N. Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan. Ann N Y Acad Sci. 1996 Dec 13;803:292-305. Review. PubMed PMID: 8993523.